U.S. Physical Therapy (USPH) insider Graham Reeve has filed a Form 144 to sell 743 shares of common stock. The proposed sale has an aggregate market value of $52,761.58 and is planned for 11/21/2025 on the NYSE through J.P. Morgan Securities LLC. Shares outstanding were 15,204,119, providing context for the size of the planned sale. The shares to be sold relate to equity compensation, as 1,948 common shares were acquired on 11/21/2025 through the vesting of restricted stock grants issued between 08/16/2021 and 02/24/2025 as payment for services. In the prior three months, Reeve sold 763 common shares on 08/21/2025 for gross proceeds of $64,832.11. The signer represents that they are not aware of undisclosed material adverse information about the company’s operations.
U.S. Physical Therapy, Inc.
The updated presentation is being shared under a Regulation FD disclosure, meaning it is intended to provide fair and equal access to information for all investors. The materials are furnished rather than filed, so they are not automatically incorporated into other securities law filings unless specifically referenced.
U.S. Physical Therapy, Inc. furnished a conference call transcript as Exhibit 99.1 under Item 7.01 (Regulation FD). The call, held on November 6, 2025, discussed results for the three and nine months ended September 30, 2025.
The company states the information is furnished, not filed, is not subject to Section 18 of the Exchange Act, and will not be incorporated by reference into Securities Act or Exchange Act filings except as expressly set forth by specific reference.
U.S. Physical Therapy (USPH) reported stronger Q3 2025 results. Net revenue rose to $197.1 million from $168.0 million a year ago, and net income attributable to shareholders increased to $13.1 million from $6.6 million. EPS was $0.48 versus $0.39 last year.
Operating income improved to $25.3 million from $12.8 million, supported by higher clinic volumes and contributions from acquired practices. For the first nine months, net revenue reached $578.3 million (vs. $490.9 million) and EPS was $1.85 (vs. $1.32).
The company ended the quarter with cash of $31.1 million, generated operating cash flow of $50.1 million year-to-date, and reported a revolving facility balance of $26.5 million and term loan of $124.4 million (non‑current). USPH added 18 clinics and closed seven in Q3, bringing owned and/or managed clinics to 779, up from 700 a year ago. Recent acquisitions included a 60% stake in a three‑clinic practice for approximately $7.9 million, plus contingent consideration tied to performance.
U.S. Physical Therapy, Inc. reported results for the three and nine months ended September 30, 2025, and attached a press release as Exhibit 99.1.
The Board declared a quarterly dividend of $0.45 per share, payable on December 12, 2025, to shareholders of record on November 17, 2025.
U.S. Physical Therapy, Inc. (USPH) received a Schedule 13G from Copeland Capital Management, LLC disclosing beneficial ownership of 843,981 shares, representing 5.54% of the common stock as of 09/30/2025.
The filer reports sole voting power over 551,532 shares, shared voting power over 144,267 shares, sole dispositive power over 0 shares, and shared dispositive power over 843,981 shares. The reporting person is classified as an investment adviser (IA). The certification and signature were provided by Sofia A. Rosala, General Counsel and CCO.
Nancy Ham, a director of U S Physical Therapy, reported selling 600 shares of the company's common stock on 09/11/2025 at $81.71 per share. After the sale she beneficially owns 1,994 shares in total. That total includes 941 restricted shares granted under the company's Amended and Restated 2003 Stock Incentive Plan, with 470 shares scheduled to lapse (vest) on November 20, 2025 and 471 shares scheduled to lapse on March 6, 2026, subject to her continuing service as a director on those dates.
US Physical Therapy Inc (USPH) Form 144 notice: The filing reports a proposed sale of 600 shares of Common stock through J.P. Morgan Securities LLC with an aggregate market value of $49,026, planned for approximately 09/11/2025 on the NYSE. The shares were acquired by vesting: 1,653 shares vested on 08/20/2025 from restricted stock grants issued between 05/16/2023 and 05/20/2025, with the acquisition characterized as payment for services rendered. The filing also discloses a prior sale of 400 shares on 06/12/2025 by Nancy Ham, generating $31,204 in gross proceeds. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Eric Joseph Williams, President and COO of U S Physical Therapy, reported a sale of 1,000 shares of the company’s common stock on 09/05/2025 at $85.25 per share. After the sale he beneficially owns 25,331 shares, which include 18,210 restricted shares subject to a multi-year vesting schedule if he remains an employee. The restricted shares vest in tranches between November 20, 2025 and March 6, 2029 as specified in the filing. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
USPH Form 4: Christopher J. Reading, Chairman and CEO of U S Physical Therapy Inc (USPH), reported a single transaction on 09/04/2025 selling 2,000 shares of the issuer's common stock at a price of $83.53 per share. After the sale he beneficially owns 114,088 shares in total. The filing discloses that 34,098 of those shares were granted as restricted stock under the companys Amended and Restated 2003 Stock Incentive Plan, with a detailed vesting schedule listing tranche dates and share counts through March 6, 2029, contingent on continued employment.